A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Absolute Bioavailability of JNJ-63623872 Administered as an Intravenous Infusion and a 600-mg Oral Dose in Healthy Adult Subjects

Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Absolute Bioavailability of JNJ-63623872 Administered as an Intravenous Infusion and a 600-mg Oral Dose in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Pimodivir (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 30 Aug 2017 Status changed from recruiting to completed.
    • 26 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 10 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top